ELTX (STOCKS)
Elicio Therapeutics, Inc. Common Stock
$10.840000
+0.690000 (+6.80%)
Prev close: $10.150000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert T. Connelly
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $199.60M
- Employees
- 26
- P/E (TTM)
- -3.96
- P/B (TTM)
- 110.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.45 | $-0.45 | +0.0039 | +0.86% |
|
Sep 2025 (Q3)
|
$-0.60 | $-0.56 | -0.0390 | -6.95% |
|
Jun 2025 (Q2)
|
$-0.66 | $-0.70 | +0.0387 | +5.54% |
|
Mar 2025 (Q1)
|
$-0.87 | $-0.85 | -0.0234 | -2.76% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $37.71M |
| Nonoperating Income/Loss | -$1.86M |
| Research and Development | $24.90M |
| Operating Income/Loss | -$37.71M |
| Income/Loss From Continuing Operations After Tax | -$39.57M |
| Income/Loss From Continuing Operations Before Tax | -$39.57M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$39.57M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$39.57M |
| Net Income/Loss Available To Common Stockholders, Basic | -$39.57M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.58 |
| Diluted Earnings Per Share | -$2.58 |
| Basic Average Shares | 15,312,751 |
| Diluted Average Shares | 15,312,751 |
| Assets | $25.86M |
| Current Assets | $19.31M |
| Noncurrent Assets | $6.55M |
| Fixed Assets | $295.00K |
| Other Non-current Assets | $6.26M |
| Liabilities | $24.23M |
| Current Liabilities | $8.11M |
| Accounts Payable | $672.00K |
| Wages | $2.53M |
| Other Current Liabilities | $4.91M |
| Noncurrent Liabilities | $16.12M |
| Long-term Debt | $10.00M |
| Other Non-current Liabilities | $6.12M |
| Equity | $1.64M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.64M |
| Liabilities And Equity | $25.86M |
| Net Cash Flow From Operating Activities | -$36.95M |
| Net Cash Flow From Operating Activities, Continuing | -$36.95M |
| Net Cash Flow From Investing Activities | -$16.00K |
| Net Cash Flow From Investing Activities, Continuing | -$16.00K |
| Net Cash Flow From Financing Activities | $36.70M |
| Net Cash Flow From Financing Activities, Continuing | $36.70M |
| Exchange Gains/Losses | $48.00K |
| Net Cash Flow | -$225.00K |
| Net Cash Flow, Continuing | -$273.00K |
| Comprehensive Income/Loss | -$39.52M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$39.52M |
| Other Comprehensive Income/Loss | -$39.52M |